Clinical Outcomes of Radiologic Relapse in Patients With Cardiac Sarcoidosis Under Immunosuppressive Therapies

Nery, 2014, Atrioventricular block as the initial manifestation of cardiac sarcoidosis in middle-aged adults, J Cardiovasc Electrophysiol, 25, 875, 10.1111/jce.12401 Winters, 1991, Sustained ventricular tachycardia associated with sarcoidosis: assessment of the underlying cardiac anatomy and the prospective utility of programmed ventricular stimulation, drug therapy and an implantable antitachycardia device, J Am Coll Cardiol, 18, 937, 10.1016/0735-1097(91)90750-4 Yazaki, 2001, Central Japan Heart Study Group. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone, Am J Cardiol, 88, 1006, 10.1016/S0002-9149(01)01978-6 Yafasova, 2020, Long-term adverse cardiac outcomes in patients With sarcoidosis, J Am Coll Cardiol, 76, 767, 10.1016/j.jacc.2020.06.038 Kandolin, 2015, Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study, Circulation, 131, 624, 10.1161/CIRCULATIONAHA.114.011522 Hamzeh, 2015, Pathophysiology and clinical management of cardiac sarcoidosis, Nat Rev Cardiol, 12, 278, 10.1038/nrcardio.2015.22 Kato, 2003, Efficacy of corticosteroids in sarcoidosis presenting with atrioventricular block, Sarcoidosis Vasc Diffuse Lung Dis, 20, 133 Terasaki, 2019, JCS 2016 guideline on diagnosis and treatment of cardiac sarcoidosis- digest version, Circ J, 83, 2329, 10.1253/circj.CJ-19-0508 Nagai, 2015, Effect of corticosteroid therapy on long-term clinical outcome and left ventricular function in patients with cardiac sarcoidosis, Circ J, 79, 1593, 10.1253/circj.CJ-14-1275 Ishida, 2014, Recommendations for 18F-fluorodeoxyglucose positron emission tomography imaging for cardiac sarcoidosis: Japanese Society of Nuclear Cardiology recommendations, Ann Nucl Med, 28, 393, 10.1007/s12149-014-0806-0 Ishimaru, 2005, Focal uptake on 18F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis, Eur Heart J, 26, 1538, 10.1093/eurheartj/ehi180 Nagano, 2015, Association Between basal thinning of interventricular septum and adverse long-term clinical outcomes in patients with cardiac sarcoidosis, Circ J, 79, 1601, 10.1253/circj.CJ-14-1217 Lang, 2005, J Am Soc Echocardiogr, 18, 1440, 10.1016/j.echo.2005.10.005 Takahama, 2017, Pathophysiology of cardiorenal syndrome in patients with heart failure: potential therapeutic targets, Am J Physiol Heart Circ Physiol, 313, H715, 10.1152/ajpheart.00215.2017 Yager, 2005, Recurrence of cardiac sarcoidosis in a heart transplant recipient, J Heart Lung Transplant, 24, 1988, 10.1016/j.healun.2005.02.016 Cacoub, 2020, Cardiac sarcoidosis: a long term follow up study, PLoS One, 15, 10.1371/journal.pone.0238391 Chiu, 2005, Prevention of left ventricular remodeling by long-term corticosteroid therapy in patients with cardiac sarcoidosis, Am J Cardiol, 95, 143, 10.1016/j.amjcard.2004.08.083 Ise, 2014, Extensive late gadolinium enhancement on cardiovascular magnetic resonance predicts adverse outcomes and lack of improvement in LV function after steroid therapy in cardiac sarcoidosis, Heart, 100, 1165, 10.1136/heartjnl-2013-305187 Cremers, 2013, Multinational evidence-based World Association of Sarcoidosis and Other Granulomatous Disorders recommendations for the use of methotrexate in sarcoidosis: integrating systematic literature research and expert opinion of sarcoidologists worldwide, Curr Opin Pulm Med, 19, 545, 10.1097/MCP.0b013e3283642a7a Birnie, 2020, Cardiac Sarcoidosis multi-center randomized controlled trial (CHASM CS− RCT), Am Heart J, 220, 246, 10.1016/j.ahj.2019.10.003